About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Marta Peris Sales, predoctoral researcher. Neurotraumatology and Neurosurgery Research Unit (UNINN). Vall d’Hebron Institute of Research (VHIR).
Abstract: Anemia is common in neurocritical care and is independently associated with secondary neurological injury and poor outcomes. Red blood cell (RBC) transfusion remains a key intervention to restore oxygen delivery to the injured brain. However, stored RBCs undergo progressive biochemical and structural changes collectively known as the “storage lesion.” These include reduced deformability, depletion of 2,3-diphosphoglycerate, oxidative membrane injury, and disturbed nitric oxide metabolism, all of which may compromise post-transfusion RBC function. In neurocritical care, such changes are of particular concern, as attenuation of cerebral oxygen delivery may occur when the injured brain has limited ischemic tolerance. The clinical relevance of RBC storage duration remains controversial, and data from general critical care populations may not be directly applicable to patients with acute brain injury, whose physiological reserve is substantially reduced. In this review, we examine the pathophysiology of the storage lesion, assess evidence on the impact of storage duration on RBC functional performance, and discuss implications for transfusion decision-making in neurocritical care, highlighting the need for brain-injury-specific research to guide evidence-based practice.
Host: Dr. Ma Antonia Poca Pastor. Head of group Neurotraumatology and Neurosurgery Research Unit (UNINN). Vall d’Hebron Institute of Research (VHIR).
Online assistance: https://gencat.zoom.us/j/87320480422